Polysaccharide modified reduction-sensitive graphene oxide carrier with organism lesion site triggered drug release and preparation and application of pharmaceutical composition thereof

A graphene and biological technology, applied in the field of preparation of the carrier, can solve the problems of slow polysaccharide degradation and shedding, hindering drug release, unfavorable curative effect, etc., and achieve good redispersibility, increased biocompatibility, and good biocompatibility Effects on sex and stability

Active Publication Date: 2015-08-12
CHINA PHARM UNIV
View PDF7 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Some polysaccharide-modified graphene oxides are now in the research stage, but these polysaccharide-modified graphene oxides still have obvious disadvantages as drug carriers: the chemical bonds connecting polysaccharides and graphene oxide are mostly amide bonds or ester bonds. The in vivo stability of this chemical bond is high, so that the degradation and shedding of polysaccharides is very slow, which

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Polysaccharide modified reduction-sensitive graphene oxide carrier with organism lesion site triggered drug release and preparation and application of pharmaceutical composition thereof
  • Polysaccharide modified reduction-sensitive graphene oxide carrier with organism lesion site triggered drug release and preparation and application of pharmaceutical composition thereof
  • Polysaccharide modified reduction-sensitive graphene oxide carrier with organism lesion site triggered drug release and preparation and application of pharmaceutical composition thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0054] Embodiment 1: the preparation of hyaluronic acid graphene oxide

[0055] 0.1mmol of hyaluronic acid, 1mmol of cystamine, 0.2mmol of EDC and 0.2mmol of NHS were dissolved in formamide. After 24 hours of reaction, the hyaluronic acid intermediate was precipitated with acetone, suction filtered and dialyzed with distilled water for 3 days (MWCO=3500) , to obtain a hyaluronic acid intermediate with a free one-terminal amino group.

[0056] 0.1 mmol of graphene oxide and 0.1 mmol of intermediates were dissolved in water, 0.4 mmol of EDC was used as an activator, and reacted for 24 hours. After the reaction, use a dialysis bag (MWCO 20000, 25000, 50000) to dialyze in distilled water at room temperature for 48 hours, filter and freeze-dry to obtain hyaluronic acid-modified graphene oxide.

Embodiment 2

[0057] Embodiment 2: the preparation of chitosan graphene oxide

[0058] 0.1mmol chitosan was dissolved in a mixed solvent of water and dimethyl sulfoxide (v / v=1:1), adding 2mmol S-aminoethyl, 3,4-dithiopropionic acid, 0.4mmol EDC and 0.4mmol NHS, reacted for 24 hours, and dialyzed in distilled water for 3 days (MWCO=3500) to obtain a chitosan intermediate with a free terminal amino group.

[0059] 0.1 mmol of graphene oxide and 0.1 mmol of intermediates were dissolved in water, 0.4 mmol of EDC was used as an activator, and reacted for 24 hours. After the reaction, use a dialysis bag (MWCO 20000, 25000, 50000) to dialyze in distilled water at room temperature for 48 hours, filter and freeze-dry to obtain chitosan-modified graphene oxide.

Embodiment 3

[0060] Embodiment 3: Preparation of low molecular weight heparin graphene oxide

[0061] 0.1mmol of low molecular weight heparin, 1mmol of cystamine, 0.2mmol of EDC and 0.2mmol of NHS were dissolved in formamide. After 24 hours of reaction, the hyaluronic acid intermediate was precipitated with acetone, suction filtered and dialyzed with distilled water for 3 days (MWCO=3500) , to obtain a low-molecular-weight heparin intermediate with a free one-terminal amino group.

[0062] 0.1 mmol of graphene oxide and 0.1 mmol of intermediates were dissolved in water, 0.4 mmol of EDC was used as an activator, and reacted for 24 hours. After the reaction, use a dialysis bag (MWCO 20000, 25000, 50000) to dialyze in distilled water at room temperature for 48 hours, filter and freeze-dry to obtain low molecular weight heparin-modified graphene oxide.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a polysaccharide modified reduction-sensitive graphene oxide carrier with organism lesion site triggered drug release. The carrier introduces polysaccharide modification into graphene oxide through a specifically degradable linking arm containing disulfide bond, so that the polysaccharide modified graphene oxide loads the drug through non-covalent acting forces and gains reduction-sensitive release characteristics. The polysaccharide modified reduction-sensitive graphene oxide loaded drug reaches the lesion site, and the linking arm of the disulfide bond can be degraded by high concentration reductive substance glutathione in the lesion cells; shedding of hydrophilic polysaccharide leads to rapid release of drug from the surface of the graphene oxide, so as to significantly improve the concentration of, efficacy and bioavailability of the free drug in lesion site. The preparation process of the present invention is simple, and the carrier has excellent biocompatibility, water solubility and lesion triggered release, and is innovative in drug delivery systems.

Description

technical field [0001] The invention belongs to the field of pharmaceutical preparations, and relates to a biospecifically degradable polysaccharide-modified graphene oxide as a drug carrier, and also relates to a preparation method and application of the carrier. Background technique [0002] The C atoms in the nanoscale graphene oxide sheets together form a large π bond, which can adsorb a large number of guest molecules, especially compounds with azoaromatic properties, through non-covalent π-π stacking, hydrophobic interactions, and hydrogen bonds. It is a very efficient carrier for such drug molecules. But at the same time, studies have shown that graphene-like carbon nanomaterials will aggregate due to the charge shielding effect under normal physiological conditions, showing extremely low stability and poor safety. However, surface modification of such materials can solve this thorny problem. Generally, graphene oxide modified with hydrophilic polymer materials will...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K47/48A61K47/36C01B31/04
Inventor 周建平霍美蓉朴玛杜殷婷婕赵媛媛
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap